Net income
-224 million USD
2025-07-01 – 2026-06-30
Fundies. English
CG Oncology, Inc.
EDGAR17 filing records in this dataset, filed from 2024-01-02 to 2026-08-06. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 19.6 million USD Source
Exact value
19636000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 88.3 million shares Source
Exact value
88306390 shares
Reported share-count change
15.84% · 12.1 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-178 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -96100000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -57236000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -132300000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -96100000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -56900000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -103400000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -56900000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
876 thousand USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Capital expenditure: 127000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 30000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 134000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 127000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 304000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 772000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 304000 USD · 2026-01-01 – 2026-03-31 Source
Free cash flow
-179 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -96100000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -57236000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -132300000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -96100000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -56900000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -103400000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -56900000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 127000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 30000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 134000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 127000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 304000 USD · 2026-01-01 – 2026-03-31 Source
- Capital expenditure: 772000 USD · 2026-01-01 – 2026-06-30 Source
- Capital expenditure: 304000 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-06.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2025-12-31
- Total assets: 3 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 3 of 11 periods available· newest 2025-12-31
- Current liabilities: 3 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 72.96 millionPrior period
−USD 88.04 million
–
Current period
−USD 161 million
–
Exact inputs and evidence
-160995000 − -88039000 = -72956000 USD
-88039000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-160995000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 53.59 millionPrior period
−USD 78.71 million
–
Current period
−USD 132.3 million
–
Exact inputs and evidence
-132300000 − -78713000 = -53587000 USD
-78713000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-132300000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-42.7%Prior period
USD 234,000
–
Current period
USD 134,000
–
Exact inputs and evidence
134000 − 234000 = -100000 USD
234000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source134000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 48.61 million Exact valueExact value: -48607000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 45.68 million Exact valueExact value: -45679000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 88.04 million Exact valueExact value: -88039000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 78.71 million Exact valueExact value: -78713000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 234,000 Exact valueExact value: 234000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 78.95 million Calculation and evidence-78713000 − 234000 USD Exact free cash flow: -78947000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 161 million Exact valueExact value: -160995000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 132.3 million Exact valueExact value: -132300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 134,000 Exact valueExact value: 134000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 132.43 million Calculation and evidence-132300000 − 134000 USD Exact free cash flow: -132434000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
17 filings · 718 latest values · 718 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001991792, 1991792, CGON, edgar:1991792
Also known as CG Oncology, Inc.